Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 10,000 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 10,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $26.88, for a total transaction of $268,800.00. Following the completion of the sale, the director directly owned 727,770 shares in the company, valued at $19,562,457.60. This represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Cyrus Harmon also recently made the following trade(s):

• On Wednesday, January 14th, Cyrus Harmon sold 3,489 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $29.12, for a total transaction of $101,599.68.
• On Monday, December 22nd, Cyrus Harmon sold 2,881 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $28.53, for a total transaction of $82,194.93.

Olema Pharmaceuticals Stock Down 1.6%

Shares of Olema Pharmaceuticals stock traded down $0.43 during trading on Wednesday, reaching $26.29. The company had a trading volume of 723,706 shares, compared to its average volume of 1,048,661. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. Olema Pharmaceuticals, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $36.26. The firm’s fifty day moving average is $26.18 and its 200-day moving average is $13.80. The company has a market cap of $1.81 billion, a price-to-earnings ratio of -14.06 and a beta of 1.92.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.05). On average, analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on OLMA shares. Guggenheim started coverage on Olema Pharmaceuticals in a research note on Wednesday, October 8th. They set a “buy” rating and a $20.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright raised their price target on shares of Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Citigroup boosted their price objective on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Finally, Piper Sandler initiated coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, January 7th. They set an “overweight” rating and a $40.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Tema Etfs LLC acquired a new stake in Olema Pharmaceuticals in the fourth quarter worth approximately $1,113,000. Nisa Investment Advisors LLC raised its stake in shares of Olema Pharmaceuticals by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after buying an additional 477 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Olema Pharmaceuticals by 83.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 447,046 shares of the company’s stock valued at $11,176,000 after buying an additional 202,970 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at $1,735,000. Finally, Susquehanna International Group LLP boosted its stake in Olema Pharmaceuticals by 20.6% during the third quarter. Susquehanna International Group LLP now owns 112,277 shares of the company’s stock valued at $1,099,000 after buying an additional 19,182 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.